A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008

Leuk Res. 2022 Dec:123:106982. doi: 10.1016/j.leukres.2022.106982. Epub 2022 Oct 22.

¹ National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation. Electronic address: [email protected].
² Department of Pediatric Oncology Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
³ National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
⁴ National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
⁵ Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
⁶ Regional Children's Hospital, Ekaterinburg, Russian Federation; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
⁷ Moscow City Blood Center named after OK Gavrilov, Moscow, Russian Federation.
⁸ Regional Children's Hospital, Ekaterinburg, Russian Federation.
⁹ Republican Children's Hospital, Moscow, Russian Federation.

No abstract available

Keywords: High-risk acute lymphoblastic leukemia; Minimal residual disease; Reduced-intensity treatment.

Publication types